Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer antibodies - ARCA biopharma

Drug Profile

Research programme: anticancer antibodies - ARCA biopharma

Alternative Names: IREM-1-antagonists; NTB-A; NTB-A-antagonists; NU 10458; NU 2444; NUVO 13759; NUVO 14453; NUVO 16587; NUVO 17289; NUVO 18778; NUVO 18832; NUVO 2788

Latest Information Update: 04 Oct 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator
  • Developer ARCA biopharma Inc
  • Class Monoclonal antibodies
  • Mechanism of Action C-type lectin-like molecule-1 protein inhibitors; CD150 antigen inhibitors; CD300LF protein antagonists; Complement activation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Leukaemia

Most Recent Events

  • 04 Oct 2012 Discontinued - Preclinical for Leukaemia in USA (Parenteral)
  • 28 Jan 2009 Nuvelo has merged with ARCA biopharma to form ARCA biopharma Inc
  • 28 Aug 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top